Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era

David Schwartz, Vishal Rana, Stephanie Shaw, Cynthia Yazbeck, Kie Kian Ang, William H. Morrison, David I. Rosenthal, Ana Hoff, Douglas B. Evans, Gary L. Clayman, Adam S. Garden, Steven I. Sherman

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background. The purpose of this study is to catalog modern-era postoperative radiotherapy (external beam radiotherapy [EBRT]) outcomes for advanced medullary thyroid cancer. Methods. Thirty-four consecutive patients with stage IVa-c disease were evaluated. Ten patients had recurrent disease, 16 had mediastinal involvement, and 10 had distant metastasis. Positive surgical margins were present in 12 cases. Median pre-EBRT serum calcitonin was 556. All patients received conformal EBRT or intensity-modulated radiotherapy. Median EBRT dose was 60 Gy and median follow-up was 46.5 months. Results. Kaplan-Meier estimates of locoregional relapse-free survival, disease-specific survival, and overall survival at 5 years were 87%, 62%, and 56%, respectively. Disease in 3 patients with gross residual disease was controlled locoregionally. Distant disease at the time of EBRT did not predict survival. Two (9%) patients reported symptomatic chronic morbidity. Conclusion. Surgery followed by EBRT provided durable locoregional disease control with limited morbidity. Postoperative EBRT merits consideration in cases of advanced disease at high risk for locoregional recurrence.

Original languageEnglish (US)
Pages (from-to)883-888
Number of pages6
JournalHead and Neck
Volume30
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Radiotherapy
Survival
Morbidity
Recurrence
Intensity-Modulated Radiotherapy
Medullary Thyroid cancer
Kaplan-Meier Estimate
Calcitonin
Disease-Free Survival
Neoplasm Metastasis
Serum

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Schwartz, D., Rana, V., Shaw, S., Yazbeck, C., Ang, K. K., Morrison, W. H., ... Sherman, S. I. (2008). Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era. Head and Neck, 30(7), 883-888. https://doi.org/10.1002/hed.20791

Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era. / Schwartz, David; Rana, Vishal; Shaw, Stephanie; Yazbeck, Cynthia; Ang, Kie Kian; Morrison, William H.; Rosenthal, David I.; Hoff, Ana; Evans, Douglas B.; Clayman, Gary L.; Garden, Adam S.; Sherman, Steven I.

In: Head and Neck, Vol. 30, No. 7, 01.07.2008, p. 883-888.

Research output: Contribution to journalArticle

Schwartz, D, Rana, V, Shaw, S, Yazbeck, C, Ang, KK, Morrison, WH, Rosenthal, DI, Hoff, A, Evans, DB, Clayman, GL, Garden, AS & Sherman, SI 2008, 'Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era', Head and Neck, vol. 30, no. 7, pp. 883-888. https://doi.org/10.1002/hed.20791
Schwartz, David ; Rana, Vishal ; Shaw, Stephanie ; Yazbeck, Cynthia ; Ang, Kie Kian ; Morrison, William H. ; Rosenthal, David I. ; Hoff, Ana ; Evans, Douglas B. ; Clayman, Gary L. ; Garden, Adam S. ; Sherman, Steven I. / Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era. In: Head and Neck. 2008 ; Vol. 30, No. 7. pp. 883-888.
@article{da04f7a9dbe14ff8ae4565340773252a,
title = "Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era",
abstract = "Background. The purpose of this study is to catalog modern-era postoperative radiotherapy (external beam radiotherapy [EBRT]) outcomes for advanced medullary thyroid cancer. Methods. Thirty-four consecutive patients with stage IVa-c disease were evaluated. Ten patients had recurrent disease, 16 had mediastinal involvement, and 10 had distant metastasis. Positive surgical margins were present in 12 cases. Median pre-EBRT serum calcitonin was 556. All patients received conformal EBRT or intensity-modulated radiotherapy. Median EBRT dose was 60 Gy and median follow-up was 46.5 months. Results. Kaplan-Meier estimates of locoregional relapse-free survival, disease-specific survival, and overall survival at 5 years were 87{\%}, 62{\%}, and 56{\%}, respectively. Disease in 3 patients with gross residual disease was controlled locoregionally. Distant disease at the time of EBRT did not predict survival. Two (9{\%}) patients reported symptomatic chronic morbidity. Conclusion. Surgery followed by EBRT provided durable locoregional disease control with limited morbidity. Postoperative EBRT merits consideration in cases of advanced disease at high risk for locoregional recurrence.",
author = "David Schwartz and Vishal Rana and Stephanie Shaw and Cynthia Yazbeck and Ang, {Kie Kian} and Morrison, {William H.} and Rosenthal, {David I.} and Ana Hoff and Evans, {Douglas B.} and Clayman, {Gary L.} and Garden, {Adam S.} and Sherman, {Steven I.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1002/hed.20791",
language = "English (US)",
volume = "30",
pages = "883--888",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Postoperative radiotherapy for advanced medullary thyroid cancer - local disease control in the modern era

AU - Schwartz, David

AU - Rana, Vishal

AU - Shaw, Stephanie

AU - Yazbeck, Cynthia

AU - Ang, Kie Kian

AU - Morrison, William H.

AU - Rosenthal, David I.

AU - Hoff, Ana

AU - Evans, Douglas B.

AU - Clayman, Gary L.

AU - Garden, Adam S.

AU - Sherman, Steven I.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background. The purpose of this study is to catalog modern-era postoperative radiotherapy (external beam radiotherapy [EBRT]) outcomes for advanced medullary thyroid cancer. Methods. Thirty-four consecutive patients with stage IVa-c disease were evaluated. Ten patients had recurrent disease, 16 had mediastinal involvement, and 10 had distant metastasis. Positive surgical margins were present in 12 cases. Median pre-EBRT serum calcitonin was 556. All patients received conformal EBRT or intensity-modulated radiotherapy. Median EBRT dose was 60 Gy and median follow-up was 46.5 months. Results. Kaplan-Meier estimates of locoregional relapse-free survival, disease-specific survival, and overall survival at 5 years were 87%, 62%, and 56%, respectively. Disease in 3 patients with gross residual disease was controlled locoregionally. Distant disease at the time of EBRT did not predict survival. Two (9%) patients reported symptomatic chronic morbidity. Conclusion. Surgery followed by EBRT provided durable locoregional disease control with limited morbidity. Postoperative EBRT merits consideration in cases of advanced disease at high risk for locoregional recurrence.

AB - Background. The purpose of this study is to catalog modern-era postoperative radiotherapy (external beam radiotherapy [EBRT]) outcomes for advanced medullary thyroid cancer. Methods. Thirty-four consecutive patients with stage IVa-c disease were evaluated. Ten patients had recurrent disease, 16 had mediastinal involvement, and 10 had distant metastasis. Positive surgical margins were present in 12 cases. Median pre-EBRT serum calcitonin was 556. All patients received conformal EBRT or intensity-modulated radiotherapy. Median EBRT dose was 60 Gy and median follow-up was 46.5 months. Results. Kaplan-Meier estimates of locoregional relapse-free survival, disease-specific survival, and overall survival at 5 years were 87%, 62%, and 56%, respectively. Disease in 3 patients with gross residual disease was controlled locoregionally. Distant disease at the time of EBRT did not predict survival. Two (9%) patients reported symptomatic chronic morbidity. Conclusion. Surgery followed by EBRT provided durable locoregional disease control with limited morbidity. Postoperative EBRT merits consideration in cases of advanced disease at high risk for locoregional recurrence.

UR - http://www.scopus.com/inward/record.url?scp=47549104319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549104319&partnerID=8YFLogxK

U2 - 10.1002/hed.20791

DO - 10.1002/hed.20791

M3 - Article

VL - 30

SP - 883

EP - 888

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 7

ER -